The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
A trio of novel cancer agent applications announced last week illustrates the breadth of oncology R&D, from targeted kinase inhibitors (Taiho Pharmaceutical Co. Ltd.’s futibatinib) to antibody-drug conjugates (ImmunoGen, Inc.’s mirvetuximab soravtansine) and radioimmunotherapy (Y-mAbs Therapeutics Inc.’s 131I-omburtamab).
Other recently submitted products aim to shake up established spaces. Outlook Therapeutics, Inc. plans to take on the widespread...
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.
To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.
